Thursday, 23 Jan 2020

You are here

Warfarin Superior to Xarelto in Antiphospholipid Syndrome

A 3 year, multicenter, European study shows that rivaroxaban was inferior to warfarin in preventing thrombosis, risk of bleeding similar in patients with the antiphospholipid syndrome (APS) according to the Annals of Internal Medicine. Thus despite the inconvenience of monitoring INR with warfarin, it is still best option for patients with APS. 

This study from Spain included 190 adults with a history of thrombotic APS. APS included those with arterial thrombosis, livedo racemosa, or APS-related cardiac valvular disease.

Patients were randomized to receive rivaroxaban (20 mg/d or 15 mg/d, according to renal function) versus dose-adjusted vitamin K antagonists (VKAs; warfarin) (target international normalized ratio, 2.0 to 3.0, or 3.1 to 4.0 in patients with a history of recurrent thrombosis). The primary efficacy outcome was the proportion of patients with new thrombotic events or major bleeding events.

After 3 years, there was more recurrent thrombosis (11 patients -11.6%) in the rivaroxaban group and 6 (6.3%) in the VKA group (RR in the rivaroxaban group, 1.83 [95% CI, 0.71 to 4.76]).

Stroke was more common with rivaroxaban (9 events vs 0 for warfarin) (RR, 19.00 [CI, 1.12 to 321.9]). Major bleeding events were similar (6.3% rivaroxaban vs. 7.4% VKA) (RR, 0.86 [CI, 0.30 to 2.46]).

The risk for recurrent thrombosis with rivaroxaban was higher with a history of previous arterial thrombosis, livedo racemosa, or APS-related cardiac valvular disease.

Rivaroxaban was associated with a non–statistically significant near doubling of the risk for recurrent thrombosis, thereby questioning the role of new oral anticoagulants in antiphospholipid antibody syndrome.


The author has no conflicts of interest to disclose related to this subject

Rheumatologists' Comments

Wow. A cheap drug is better???

More Like This

Steroid-Sparing Effect of Tocilizumab in Refractory Takayasu Arteritis

A controlled clinical trial has shown that giving the IL-6 receptor antibody, tocilizumab (TCZ), to  patients with Takayasu arteritis (TAK) results in clinical efficacy and has a steroid sparing efffect.

TULIP2 - Anifrolumab Succeeds in Lupus

NEJM has published the results of the TULIP2 trial with anifrolumab, an alpha interferon blocker, in the treatment of systemic lupus erythematosus, showing significant improvement (over placebo) in multiple lupus outcome measures, including BICLA, SRI-4, CLASI and others.

Steroids Up the Risk of Organ Damage in SLE

Lancet Rheumatology has reported the results of a multicenter follow-up study of systemic lupus erythematosus (SLE) patients showing that organ damange is linked to glucocorticoid use, independent of clinical or serological disease activity.

Treatment of Statin-induced anti-HMGCR myopathy

Statin-induced myositis, often with anti-HMGCR autoantibodies can be difficult to manage, Arthritis Research & Therapy yhas published the experience of 55 patient with HMGCR myopathy, demonstrating that while steroid management may be reasonable in select patients, the use of triple steroid/IVIG/SSI was very efficacious in induction.

Best of 2019 - 2019 EULAR Guidelines on Antiphospholipid Syndrome Management

A EULAR task force has reviewed the medical literature and developed evidence-based recommendations for the management of antiphospholipid syndrome (APS) in adults. They note that a high-risk antiphospholipid antibody (aPL) profile is associated with greater risk for thrombotic and obstetric APS.